Please Note: Study Closed
Please note that we are no longer accepting registrants to this clinical trial. It has been closed.
Clinical Trial For Dogs With Osteosarcoma
Osteosarcoma is an aggressive cancer that frequently arises in the long bones of large-breed dogs. Approximately 90-95% of dogs with osteosarcoma have undetectable metastatic disease at presentation. Despite limb amputation and follow-up chemotherapy, most dogs are euthanized due to progressive metastatic disease within a year of diagnosis.
Dogs enrolled in this upcoming clinical trial will receive a HER2-targeting bacterial vaccine after amputation and chemotherapy. This immunotherapy has shown promising results in preventing metastatic disease when evaluated in a small number of dogs with osteosarcoma after surgery and chemotherapy.
- Dogs with a histopathological diagnosis of appendicular osteosarcoma
- Dogs that have undergone limb amputation followed by 4-6 doses of carboplatin chemotherapy
- Dogs that are otherwise healthy
- Dogs that reside in PA, DE, NJ, MD, CT, NY, CA, AZ, or NV
- Evidence of metastatic disease at screening
- Concurrent use of other chemotherapy or immunotherapy
The study will pay for:
- All visits and clinical and diagnostic tests associated with the clinical trial
- Three doses of vaccine
- Treatment of any side effects associated with the vaccine
The study does not pay for initial diagnostic tests, amputation, or chemotherapy.
Dr. Nicola Mason